Sequent Scientific Ltd

Viyash Scientific Limited closes trading window from Thursday, October 01, 2026 until 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter ending on September 30, 2026.

ESOP allotment and capital update

• 9,26,333 shares issued under Sequent ESOP 2020 at Rs 86 per share.
• 1,80,976 shares issued under Viyash ESOP 2026 at Rs 101 per share.
• Total issued equity shares increased to 44,16,27,670.
• Issued share capital increased from Rs 88,10,40,722 to Rs 88,32,55,340.
• Post-allotment shares rank pari passu with existing equity shares.
• Approval dated Sept 18, 2026 by Nomination and Remuneration Committee via circulation.

Acquisition update

• Proposed acquisition intends 100% shareholding in BioForLife Italia S.r.l. by Alivira Animal Health Limited.
• Regulatory approval under Italian FDI/Golden Power received.
• Completion now expected within two months from intimation date (Sept 8, 2026).
• Other material terms unchanged; June 8 and July 21, 2026 disclosures remain in effect.
• Remaining customary closing formalities and closing conditions apply.

Target and Disclosing Parties

• Target Company: Viyash Scientific Limited.
• Sellers/Disclosing Parties: CA Harbour Investments and CA Hull Investments (promoters).

Pre-Transaction Holdings

• CA Harbour pre-holding: 13,16,80,103 shares (30.14%).
• CA Hull pre-holding: 13,61,60,231 shares (31.17%).

Post-Transaction Holdings and Sale

• CA Harbour post-holding: 10,69,18,412 shares (24.47%).
• CA Hull post-holding: 11,05,56,075 shares (25.31%).
• CA Harbour sold: 2,47,61,691 shares (5.67%).
• CA Hull sold: 2,56,04,156 shares (5.86%).

Capital Context and Transaction Details

• Mode: Open Market.
• Date of sale: August 26, 2026.
• Total equity capital before/after: 87,37,50,954 shares.
• Post-diluted TC capital: Harbour 95,98,57,830; Hull 47,99,28,915.

Meeting Details

• Date: August 12, 2026
• Type/Mode: Earnings conference call; virtual
• Event/Organizer: Viyash Scientific Limited Q1 FY’27 Earnings Conference Call

Participants

• Managing Director & Group Chief Executive Officer
• Executive Director & Chief Executive Officer, Animal Health
• Chief Financial Officer

Purpose

• Discuss Q1 FY’27 results; share highlights of business and financials
• Investor Q&A

Additional Notes

• Conference is being recorded
• Transcript will be available on company website within a week
• Results release and Investor Presentation uploaded on website and stock exchanges

Meeting Details

• Date of call: August 12, 2026.
• Type: earnings call; format: audio recording.
• Coverage: unaudited consolidated and standalone results for quarter ended June 30, 2026.

Participants

• Key participant: Company Secretary & Compliance Officer.

Purpose

• Discuss unaudited consolidated and standalone results for quarter ended June 30, 2026.

Additional Notes

• Recording available on the company website.

Business Overview

• Integrated pharmaceutical platform across human and animal health with API and formulation R&D.
• Backward integration across 16 manufacturing facilities for key APIs.
• Global footprint: 150+ countries and 250+ global customers.
• Companion animal focus expanding via Italy acquisition to access large EU market.
• Strategic growth: disciplined execution, efficiency, and long-term investments.

Operational Highlights

• Bio For Life acquisition SPA executed 21 July 2026; closing expected September 2026.
• Italy market access; salesforce covers 85% of vet clinics.
• Companion animal portfolio size ~85–90 products; expansion to core markets.
• Launches: 6 APIs and 4 FDFs across regions.
• Regulatory progress: 3 APIs (USDMF/EDMF/CEP) and 2 US FDF approvals.
• R&D scale: 85+ API and 24+ human FDF pipeline; 81+ animal FDF.
• Regulatory inspections: 4 regulatory audits; 66 customer audits.
• Manufacturing footprint: 16 facilities; ongoing backward integration.

Financial Performance

• Q1 FY27 revenue from operations ₹9,464 Mn, up 19.5% YoY.
• Gross margin 54.1%; EBITDA ₹2,047 Mn with 21.6% margin.
• PAT ₹793 Mn in Q1 FY27; YoY growth 114.9%.
• EBT ₹1,124 Mn; Taxes ₹331 Mn; Finance cost ₹125 Mn.
• FY26 revenue ₹34,203 Mn; YoY growth 14%.
• FY26 PAT ₹2,246 Mn; FY25 ₹158 Mn.
• Revenue mix highlights growth driven by Formulations and Emerging Markets.

Capital Structure & Liquidity

• Finance cost declined to ₹125 Mn in Q1 FY27 from ₹204 Mn prior year.
• No new debt or equity raise disclosed in quarter.

Strategic Priorities & Outlook

• Long-term strategy: disciplined execution, operational efficiency, and strategic investments for sustainable growth.
• Companion animal focus to drive growth via Italy and broader Europe.
• Pipeline: 85+ APIs and 81+ animal FDFs; opportunities in CDMO and oncology.
• M&A and geography expansion to sustain growth.

Risks & Mitigation

• Italy acquisition closing remains subject to regulatory approvals.
• Integration risks of Bio For Life; execution and regulatory timelines.
• Regulatory and market risks acknowledged; emphasis on disciplined execution.

Governance

• Chairman: Dr. Kamal Sharma; MD & CEO: Dr. Haribabu Bodepudi.
• Board includes independent directors; Company Secretary Yoshita Vora.
• No material governance changes disclosed.

AGM Details

• Forty-first AGM held on Aug 11, 2026 at 4:00 PM IST via VC/OAVM.
• Cut-off date for voting: Aug 4, 2026.
• Total shareholders on record: 133,984.
• Remote e-voting window: Aug 7-10, 2026.

Resolutions & outcomes

• Resolution 1: Adoption of Audited Financial Statements for FY2025-26 - passed; 1,214 against.
• Resolution 2: Re-appointment of Dr. Haribabu Bodepudi - passed; 421,263 against.
• Resolution 3: Re-appointment of Rajaram Narayanan - passed; 1,678 against.
• Resolution 4: Ratification of revised remuneration to Cost Auditor for FY2025-26 - passed; 1,680 against.
• Resolution 5: Ratification of remuneration to Cost Auditor for FY2026-27 - passed; 1,631 against.
• Resolution 6: Adoption of new Articles of Association - passed; 5,107 against.

Directors

• Directors re-appointed: Dr. Haribabu Bodepudi and Rajaram Narayanan.

Auditors

• Cost Auditor remuneration approved for FY2025-26 and FY2026-27.

AGM Details

• AGM held on 11 August 2026 at 4:00 PM via VC/OAVM.
• Meeting concluded at 4:55 PM IST.

Key Resolutions

• Adoption of Audited Financial Statements for year ended March 31, 2026 (Ordinary).
• Re-appointment of Dr. Haribabu Bodepudi as Director, retiring by rotation (Ordinary).
• Re-appointment of Rajaram Narayanan as Director, retiring by rotation (Ordinary).
• Ratification of remuneration payable to Cost Auditor for FY 2025-2026 (Ordinary).
• Ratification of remuneration payable to Cost Auditor for FY 2026-2027 (Ordinary).
• Adoption of a new set of Articles of Association (Special).

Voting Status

• Voting results to be announced within statutory timelines and intimated to stock exchanges.